Problem with Clinical Materials Forces Benitec To Delay Filing IND for HIV/AIDS Therapy | GenomeWeb

Benitec has delayed the filing of an investigational new drug application for its RNAi-based HIV/AIDS therapy after the company discovered "one aberrant result in the release tests of the clinical materials," the firm said this week.

Benitec had been planning to begin a phase I trial of the therapy — the most advanced in its development pipeline — in the first half of this year. However, this timeline has been pushed back indefinitely, Benitec CEO Sara Cunningham told RNAi News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.